



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

Date: 30.05.2017

1. The Secretary,
Bombay Stock Exchange Ltd
Phiroze Jeejeebhoy Towers
Dalal Street, MUMBAI 400 001

2. The Secretary,
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra (E), MUMBAI 400 051

3. The Secretary,
Ahmedabad Stock Exchange Ltd
Kamdhenu Complex
Opp Sahajanand College
Panjarpole, AHMEDABAD 380 015

ISIN: INE448G01010

Sub: Outcome of Board meeting
Dear Sir,

The Board of Directors' meeting was held on 30.05.2017 the following is the outcome of the same;

1. The Audited results for the year ended 31st march 2017 were approved. The same are attached herewith for your reference.
2. The Audited Balance Sheet of the Company as at March 31, 2017 and Statement of Profit & Loss for the year ended as on that date together with the Reports of Directors and Auditors thereon was approved.
3. The date of Annual General Meeting is Thursday, 24th August 2017.
4. The date of Book closure of the company will be from 17th August 2017 to 24th August 2017 both days inclusive

Thanking You,
Yours faithfully,
For Nath Bio-Genes (India) Limited,

Asst Manager (Secretarial)
Krutika Apté



LIMITED REVIEW REPORT

To
The Board of Directors of
NATH BIO-GENES (INDIA) LIMITED.

We have audited the accompanying statement of quarterly financial results of Nath Bio-Genes (India) Limited for the quarter ended 31.03.2017 and the year to date results for the period from 01.04.2016 to 31.03.2017, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended, 31.03.2017 as well as the year to date results for the period from 01.04.2016 to 31.03.2017

For Gautam N Associates
Chartered Accountants
FRN : 103117W


(Gautam Nandawat)
Partner
M N :032742



Place: Aurangabad
Dated: 30.05.2017



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

FORM A (FOR AUDIT REPORT WITH UNMODIFIED OPINION) OR FORM B (FOR AUDIT REPORT WITH MODIFIED OPINION) ALONG-WITH FINANCIAL RESULTS


FORM A (for audit report with unmodified opinion)

1	Name of the company	Nath Bio-Genes (India) Limited
2	Annual financial statements for the year ended	31 st March 2017
3	Type of Audit observation	Unmodified
	Frequency of Observation	Not Applicable

The above is for your kind information and record.

For Nath Bio-Genes (India) Limited

x 
Managing Director
Satish Kagliwal


Kashinath Iyer
Chairman, Audit Committee


Devinder Khurana
Chief Financial Officer

For Gautam N Associates
Chartered Accountants
FRN: 103117W


(Gautam Nandawat)
Partner
M N: 032742

Date: 30.05.2017
Place: Aurangabad



NATH SEEDS™

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31/03/2017

	Three Months Ended			Twelve Months Ended	
	31/03/2017 Audited	31/12/2016 Unaudited	31/03/2016 Audited	31/03/2017 Audited	31/03/2016 Audited
1 Net Sales / Income from operations	5076.98	1817.29	2829.33	16972.56	16210.59
2 Expenses					
a) Cost of Material Consumed	448.68	2201.58	1045.67	6042.50	7795.86
b) Changes in Inventory	1672.13	(1609.31)	(649.32)	1040.42	(2442.00)
c) Employee benefit expense	366.86	334.01	213.83	1373.61	1363.44
d) Selling & Distribution Expenses	1363.45	235.62	1224.44	3903.67	5032.64
e) Depreciation & Amortisation	39.73	87.97	(0.95)	303.04	390.48
f) Other Expenditure	1149.02	134.34	1264.10	1727.25	2008.27
g) Total	5039.86	1384.21	3097.77	14390.48	14148.69
3 Profit from Operations before Other	37.12	433.08	(268.44)	2582.08	2061.90
4 Other Income	29.87	8.93	46.48	65.91	70.82
5 Profit before Interest & Other Items	66.99	442.01	(221.96)	2647.99	2132.72
6 Finance Costs	291.37	264.75	65.90	965.71	623.09
7 Profit before Exceptional Items	(224.38)	177.26	(287.86)	1682.28	1509.63
8 Exceptional Items	0.00	0.00	0.00	0.00	0.00
9 Profit/(Loss) before Tax	(224.38)	177.26	(287.86)	1682.28	1509.63
10 Tax expense	(12.90)	60.00	71.00	47.10	91.00
11 Net Profit / (Loss) after Tax	(211.48)	117.26	(358.86)	1635.18	1418.63
12 Extraordinary Items	6.86	0.00	0.04	6.94	1.88
13 Net Profit / (Loss) for the period	(218.33)	117.26	(358.90)	1628.25	1416.75
14 Share of Profit/(Loss) of Associates	0.00	0.00	0.00	0.00	0.00
15 Minority Interest	0.00	0.00	0.00	0.00	0.00
16 interest	(218.33)	117.26	(358.90)	1628.25	1416.75
17 Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1600.40	1600.40	1600.40	1600.40	1600.40
18 Reserves (excluding Revaluation)	12158.24	12376.58	10530.00	12158.24	10530.00
19 Basic and Diluted EPS	(1.36)	0.73	(2.24)	10.17	8.85

NOTES:

- (1) Above financial results are taken on record by the Board of Directors in their meeting held on 30th May 2017.
- (2) The company is constantly improving its Product Mix for better profits.
- (3) The company has launched 12 new research products in various crops during the year.
- (4) The company is dealing in one major product segment, i.e. seeds for cultivation.
- (5) Investor complaints - Opening Balance - 0, Received and Solved - 2, Closing Balance - 0
- (6) The figures for the Quarter ending 31.03.2017 are the balancing figures between audited figures of the full financial year and the year to date figures up to the third quarter.
- (7) The earlier period figures have been regrouped / rearranged where necessary.

FOR NATH BIO-GENES (INDIA) LTD

Place : Aurangabad


Date : 30 May 2017


 Satish Kagliwal

MANAGING DIRECTOR

DIN 00119601

 Regd. Office : Nath House, Nath Road, Aurangabad - 431005 (MS)
 www.nathbiogenes.com

FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

GAUTAM NANDAWAT
 (Partner)


Nath Bio-Genes (India) Limited
Standalone Statement of Assets and Liabilities

Rs. In Laacs

Particulars	As at year end 31.03.2017 (Audited)	As at previous year end 31.03.2016 (Audited)
A EQUITIES AND LIABILITIES		
1. Shareholders' Fund		
(a) Share capital	1600.40	1600.40
(b) Reserves and Surplus	12158.24	10530.00
(c) Money received against share warrants	0.00	0.00
Sub-total - Shareholders' Fund	13758.64	12130.40
2. Share application money pending for allotment	0.00	0.00
3. Minorities Interest	0.00	0.00
4. Non-current liabilities		
a) Long Term Borrowings	2006.71	1500.00
b) Deferred Tax Liabilities	0.00	0.00
c) Other Long Term Liabilities	0.00	0.00
d) Long Term Provisions	200.65	178.64
Sub-total - Non-current liabilities	2207.36	1678.64
5. Current Liabilities		
a) Short Term Borrowings	4860.88	4304.48
b) Trade Payables	4435.28	4795.13
c) Other Current Liabilities	3418.67	3540.21
d) Short Term Provisions	254.59	221.15
Sub-total - Current liabilities	12969.42	12860.97
TOTAL - EQUITY AND LIABILITIES	28935.42	26670.01
B ASSETS		
(1) Non Current Assets		
a) Fixed Assets	4156.59	3046.36
b) Non Current Investments	499.68	0.26
c) Deferred Tax Assets (Net)	85.41	86.86
d) Long Term Loans and Advances	0.00	1009.51
e) Other Non Current Assets	0.00	0.00
Sub-total - Non Current Assets	4741.68	4142.99
(2) Current Assets		
a) Current Investments	0.00	499.40
b) Inventories	13015.09	14073.98
c) Trade Receivables	5182.46	4531.14
d) Cash and Cash Equivalents	584.70	122.44
e) Short Term Loans and Advances	5308.44	3184.75
f) Other Current Assets	103.06	115.31
Sub-total - Current Assets	24193.75	22527.02
TOTAL ASSETS	28935.42	26670.01
	0.00	0.00

FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

Gautam
GAUTAM NANDAWAT
(Partner)



FOR NATH BIO-GENES (INDIA) LTD

Satish

Satish Kagliwal
MANAGING DIRECTOR
DIN 00119601

Place : Aurangabad
Date : 30th May 2017